Theralase Technologies Inc. (CVE:TLT - Get Free Report) shares were up 10.2% during trading on Tuesday . The stock traded as high as C$0.28 and last traded at C$0.27. Approximately 223,000 shares changed hands during mid-day trading, an increase of 115% from the average daily volume of 103,522 shares. The stock had previously closed at C$0.25.
Theralase Technologies Stock Performance
The company has a market cap of C$67.52 million, a P/E ratio of -13.75 and a beta of 1.36. The business has a 50 day moving average price of C$0.27 and a two-hundred day moving average price of C$0.23. The company has a debt-to-equity ratio of 20.58, a quick ratio of 3.40 and a current ratio of 1.21.
About Theralase Technologies
(
Get Free Report)
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
Before you consider Theralase Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.
While Theralase Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
